Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12230246 | 0.76 | KMT2A (0.86) | KDM4ESMN1; SMN2POLBTDP1ALDH1A1 | |
| SCHEMBL3431552 | 0.76 | KMT2A (0.91) | SMN1; SMN2POLBTDP1ALDH1A1KMT2A | |
| SCHEMBL14387700 | 0.75 | MAPT (1.00) | KDM4EPOLBTDP1ALDH1A1HSD17B10 | |
| SCHEMBL12230242 | 0.75 | KMT2A (0.69) | KDM4ESMN1; SMN2POLBTDP1ALDH1A1 | |
| SCHEMBL30975216 | 0.74 | RAB9A (0.76) | KDM4ESMN1; SMN2ALDH1A1HSD17B10KMT2A | |
| SCHEMBL9998600 | 0.73 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1HSD17B10KMT2A | |
| SCHEMBL12230243 | 0.73 | KMT2A (0.66) | KDM4ESMN1; SMN2POLBTDP1ALDH1A1 | |
| SCHEMBL6176249 | 0.73 | MAPT (0.72) | KDM4EPOLBTDP1ALDH1A1HSD17B10 | |
| SCHEMBL21586272 | 0.72 | ALDH1A1 (0.80) | SMN1; SMN2POLBALDH1A1HSD17B10KMT2A | |
| SCHEMBL14207708 | 0.72 | KMT2A (0.69) | KDM4ESMN1; SMN2POLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906937-B2 | Flavivirus inhibitors and methods of their use | GEORGETOWN UNIVERSITY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140038962-A1 | Flavivirus Inhibitors and Methods of Their Use | GEORGETOWN UNIVERSITY (US) | 2014-02-06 | — | — | US | disclosed |
| US-8563580-B2 | Flavivirus inhibitors and methods for their use | GEORGETOWN UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110224207-A1 | FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE | GEORGETOWN UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224207-A1 | FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE | SERPINB1, SPINT2, MME | KDM4E 2141/4885SMN1; SMN2 855/4885POLB 3870/4885 |
| US-20140038962-A1 | Flavivirus Inhibitors and Methods of Their Use | SERPINB1, SPINT2, MME | KDM4E 2560/4885SMN1; SMN2 1025/4885POLB 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.